Stockscreener 앱 받기
157.58
2.79%
-4.3601
전일 마감가:
$161.94
열려 있는:
$159.74
하루 거래량:
1.01M
Relative Volume:
0.81
시가총액:
$16.02B
수익:
$3.10B
순이익/손실:
$668.60M
주가수익비율:
24.23
EPS:
6.5044
순현금흐름:
$831.30M
1주 성능:
-2.53%
1개월 성능:
-11.12%
6개월 성능:
+27.88%
1년 성능:
+22.13%
1일 변동 폭
$154.86
$159.98
1주일 범위
$154.86
$165.46
52주 변동 폭
$122.14
$186.12
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
157.62 | 16.46B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
17.41 | 55.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.80 | 43.73B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.62 | 42.51B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.32 | 31.14B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
519.38 | 22.11B | 3.17B | 1.29B | 1.01B | 27.09 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences Shares Drop Amid Vykat Safety Reports - StockInvest.us
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Neurocrine Biosciences shares fall amid Vykat safety concerns - finance.yahoo.com
Neurocrine Biosciences stock falls on Vykat safety concerns - Investing.com
Neurocrine study shows Ingrezza improved tardive dyskinesia symptoms By Investing.com - Investing.com India
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia - PR Newswire
Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ) - Seeking Alpha
Why is Neurocrine Biosciences stock down today? By Investing.com - Investing.com Canada
Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Liquidity Mapping Around (NBIX) Price Events - Stock Traders Daily
Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing? - Sahm
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Neurocrine Biosciences, Inc. (NB3.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeat
Healthcare Stocks Investors Are Watching For Steady Demand After Weak US Jobs Data - Sahm
How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine starts phase 1 trial of obesity drug candidate - Investing.com
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist - PR Newswire
Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC - MarketBeat
Zacks Research Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Hold - MarketBeat
Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift - Stock Titan
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount - ChartMill
The Manufacturers Life Insurance Company Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Quantinno Capital Management LP Buys 42,508 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
BDF Gestion Invests $2 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Private Client Services LLC Trims Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amundi Raises Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress - Investing.com
H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A Deep Dive into a 26.55% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Royal Bank of Canada - MarketBeat
Perceptive Advisors LLC Sells 266,000 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – SWB:NB3 - TradingView
Arete Wealth Advisors LLC Invests $3.04 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Guggenheim raises Neurocrine Bio stock price target on Ingrezza beat By Investing.com - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus - simplywall.st
Neurocrine Biosciences, Inc. Revenue Breakdown – NASDAQ:NBIX - TradingView
JPMorgan Chase & Co. Boosts Neurocrine Biosciences Inc (NBIX) St - GuruFocus
Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact - Stock Titan
NEUROCRINE BIOSCIENCES INC 2026: Revenue $959M, EPS $1.39— 10-Q Summary - TradingView
Neurocrine Biosciences Q2 Earnings Call Highlights - MarketBeat
Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $208.59, Implies 12% Upside - TradingView
Neurocrine Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Form 4 Neurocrine Biosciences Inc For: 30 July By Investing.com - Investing.com Nigeria
NEUROCRINE BIOSCIENCES INC NEUR (0K6R.L) Q2 FY2026 earnings call transcript - finance.yahoo.com
Neurocrine Biosciences Q2 revenue rises 39% to $959 million - Quiver Quantitative
Neurocrine: Q2 Earnings Snapshot - 10tv.com
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Norwalk Leslie V | Director |
Jul 28 '26 |
Sale |
182.01 |
1,250 |
227,508 |
1,588 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Option Exercise |
106.02 |
4,367 |
462,989 |
20,592 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Sale |
181.02 |
4,367 |
790,514 |
16,225 |
| Lippoldt Darin | Chief Legal Officer |
Jul 09 '26 |
Option Exercise |
81.49 |
10,000 |
814,900 |
64,729 |
| Lippoldt Darin | Chief Legal Officer |
Jul 09 '26 |
Sale |
179.60 |
10,000 |
1,796,014 |
54,729 |
0.12%
3.54%
자본화:
|
볼륨(24시간):